Thrombin-activatable fibrinolysis inhibitor; Carboxypeptidase B2; Single nucleotide polymorphism; Cardiovascular and cerebrovascular diseases; CCVD; Meta-analysis

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases

S. W. Wang, Zhang, H. H., Dong, C. Y., Sun, H. H., Wang, S. W., Zhang, H. H., Dong, C. Y., Sun, H. H., Wang, S. W., Zhang, H. H., Dong, C. Y., and Sun, H. H., Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases, vol. 15, p. -, 2016.

Cardiovascular and cerebrovascular diseases (CCVDs) are common and have high rates of morbidity, mortality, and recurrence. Thrombin-activatable fibrinolysis inhibitor (TAFI) is also known as carboxypeptidase B2 and is encoded by the CPB2 gene; CPB2 polymorphisms have been explored in a variety of studies, but their correlation to the risk of CCVDs remains ambiguous. We examined the hypothesized associations between CPB2 mutations and CCVDs in a general population.

Subscribe to Thrombin-activatable fibrinolysis inhibitor; Carboxypeptidase B2; Single nucleotide polymorphism; Cardiovascular and cerebrovascular diseases; CCVD; Meta-analysis